# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK‐875: Results From a Double‐Blind, Placebo‐Controlled Single Oral Dose Rising Study in Healthy Volunteers

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/safety-tolerability-pharmacokinetics-and-pharmacodynamic-properties-of-the-gpr40/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Himanshu Naik,Majid Vakilynejad,Jingtao Wu,Prabhakar Viswanathan,Nobuhito Dote,Tomoaki Higuchi,Eckhard Leifke |
| Citations | 88 |
| DOI | 10.1177/0091270011409230 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2147024197 |
| PMID | 21610201 |
| Type | article |
| Year | 2011 |

## Paper authors

- [Eckhard Leifke](https://scholariq.org/researchers/eckhard-leifke/)

## Paper journal

- [The Journal of Clinical Pharmacology](https://scholariq.org/journals/the-journal-of-clinical-pharmacology/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Receptor Mechanisms and Signaling](https://scholariq.org/topics/receptor-mechanisms-and-signaling/)
- [Hyperglycemia and glycemic control in critically ill and hospitalized patients](https://scholariq.org/topics/hyperglycemia-and-glycemic-control-in-critically-ill-and-hospitalized-patients/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.